Next Arc Research

Not logged in? You're viewing the Free tier. Join for free or log in to access your membership content.
Disclaimer: This content is for informational and educational purposes only and should not be construed as financial or investment advice. Always do your own research and consult a licensed financial advisor before making investment decisions.
Disclosure: The author does not hold a position in NNOX.
← Back to Free Index

NNOX

Analysis as of: 2026-06-21
Nano-X Imaging Ltd.
Nanox sells digital imaging systems plus remote radiology, imaging AI, cloud workflow, and healthcare IT services to providers.
ai hardware healthcare medical devices software
On Yahoo Finance ...
Jump to: Summary • Analysis • Opportunity • Risk • Trends • LE Structure • Third Party Analyst Consensus

Summary

Low-Cost Imaging Option, Still Runway-Gated
The upside is meaningful because the valuation base is tiny and a working installed-base flywheel could rerate the business sharply. But the near-term burden of proof is still basic: funding, activations, and evidence that systems become recurring workflow revenue.

Analysis

Thesis
Nanox is a cheap option on turning lower-cost 3D imaging into a recurring imaging utility; if it secures runway, completes outsourcing, and converts distributor agreements into live, scanning sites, revenue can grow non-linearly from service and software attach, but the path remains funding- and activation-gated.
Last Economy Alignment
Moderately positive: AI makes each installed system more valuable through workflow, remote reads, and software attach, but capital, approvals, and incumbent trust still cap value capture.
Upgrade to Allocator to also access: Thesis Critique

Opportunity Outlook

Average Implied 5-Year Multiple
7.7x (from 5 most recent analyses)
Reasoning
The upside case does not require Nanox to win mainstream imaging. It only needs to prove that a modest installed base can become a recurring workflow node for remote reads, AI, cloud, and health IT. Because the current enterprise value is very small, credible evidence of activation, lower hardware losses, and recurring mix can drive a meaningful rerating even if the company remains niche versus large imaging incumbents.
Upgrade to Allocator to also access: Simplified Opportunity Explanation

Risk Assessment

Overall Risk Summary
This is a sequence-risk story. Nanox first needs enough capital to keep moving, then faster deployment-to-activation conversion, then proof that each live system supports recurring software, remote-reading, and IT revenue with improving hardware economics. The upside is real because the valuation base is tiny, but missing any gate can force dilution before the flywheel forms.
Upgrade to Allocator to also access: Tech Maturity Risk Score, Adoption Timing Risk Score, Moat Strength Risk Score, Capital Needs Risk Score, Regulatory Risk Score, Execution Risk Score, Concentration Risk Score, Unit Economics Risk Score, Valuation Risk Score, Macro Sensitivity Risk Score

Last Economy Structure

AI Industrial Score
0.25
They control a cleared imaging device plus the workflow around reading and health IT, so AI can make each installed system more valuable over time. The risk is that bigger vendors already own trust, financing, and service channels, while funding and permits slow this company before its flywheel forms.
Upgrade to Reader to also access: Score Decomposition, Confidence Level
Upgrade to Allocator to also access: Obsolescence Vectors, Pricing Fragility
Upgrade to Reader to also access: Constraint Benefit Score, Obsolescence Risk Score

Third Party Analyst Consensus

12-Month Price Target
$6.65
Upgrade to Reader to also access: Bull Case, Base Case, Bear Case